Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mariana Gonzalez-Trevino¹, Jeffrey Yang², Larry J. Prokop³, Gabriel Figueroa-Parra¹ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
Abstract Number: 1944 • ACR Convergence 2023
Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre
Arturo Llobell¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor Mora-Cuesta³, Marcos Lopez-Hoyos⁴, Jose Cifrian⁵ and Ricardo Blanco⁶, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁴Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) comprises a wide range of disorders categorized by clinical, radiographic and pathologic findings that is closely associated with autoimmune connective…
Abstract Number: 2465 • ACR Convergence 2023
Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen
Lindsay Bass¹, Dena Liu¹, Alberto Cisneros², Jennifer Young-Glazer², Leslie Crofford³, Erin Wilfong² and Rachel Bonami², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS) is defined by the presence of autoantibodies against histidyl tRNA synthetase (Jo-1). Clinically, Jo-1 ARS can involve multiple tissues…
Abstract Number: 0106 • ACR Convergence 2023
Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds
Junna Ye¹, Yijun You², Zhuochao Zhou², Fan wang², Jingyi Wu² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Persistent presence of antiphospholipid antibodies (aPLs) are important thrombosis-related laboratory parameters, as well as an indication of anticoagulation use which usually cause higher bleeding…
Abstract Number: 0608 • ACR Convergence 2023
Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
Anca Askanase¹, David D'Cruz², Kenneth Kalunian³, Joan Merrill⁴, Sandra Navarra⁵, Clélia Cahuzac⁶, Peter Cornelisse⁶, Daniel Strasser⁶, Luba Trokan⁷ and Ouali Berkani⁸, ¹Columbia University Medical Center, New York, NY, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁶Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ⁷Idorsia Pharmaceuticals Ltd. at time of data generation, Allschwil, Switzerland, ⁸IDORSIA, Allschwil, Switzerland
Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…
Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 1475 • ACR Convergence 2023
Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer
Shivani Shah¹, chandana keshavamurthy¹, Samantha Ahrens¹, Douglas Reeves¹, William Davis¹, Robert Quinet¹, Jerald Zakam¹, Samina Hayat², Teresa Leeth², Sarwat Umer³, Sulman Hasan², Maria Latsis², Xin Zhang¹ and Gitanjali Lobo⁴, ¹Ochsner Health, New Orleans, LA, ²Louisiana State University, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibodies and systemic inflammation, affecting multiple organs especially kidney. Environmental factors, genetic predisposition,…
Abstract Number: 1949 • ACR Convergence 2023
Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis
Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan
Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…
Abstract Number: 2466 • ACR Convergence 2023
Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein
Eveline Van Gompel¹, Ragnhild Stålesen², Caroline Grönwall², Annika van Vollenhoven², Lena Israelsson², Ingrid Lundberg³, Vivianne Malmström², Karine Chemin⁴ and Vijay Joshua², ¹Karolinska Institutet - KU Leuven, Leuven, Belgium, ²Karolinska Institutet, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The strong clinical association between the anti-MDA5 autoantibodies and the development of severe lung disease in patients with dermatomyositis (DM) suggests an active role…
Abstract Number: 067 • 2023 Pediatric Rheumatology Symposium
Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis
Yike Jiang, Alexander Sandweiss, Timothy Erickson, Eyal Muscal and Kristy Murray, Baylor College of Medicine, Houston, TX
Background/Purpose: The discovery of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis heralded a new class of neuropsychiatric illnesses mediated by autoantibodies, known collectively as autoimmune encephalitis. The clinical…
Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Yiressy Pina¹, Dawn Janysek¹, Danielle Guffey², Maria Pereira Palacios³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Dawn Janysek¹, Yiressy Pina², Danielle Guffey³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 0639 • ACR Convergence 2022
Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity
Robert Clancy¹, Joel Guthridge², Miranda Marion³, Hannah Ainsworth⁴, Marci Beel², Christina Firl⁵, Nicola Fraser⁶, Nour Hachemian⁵, Timothy Howard⁴, Peter Izmirly¹, Mala Masson⁷, Melissa Munroe², Jill Buyon¹, Judith James² and Carl Langefeld⁸, ¹NYU Grossman School of Medicine, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Wake Forest University, Winston-Salem, NC, ⁴Wake Forest School of Medicine, Winston-Salem, NC, ⁵NYU Langone Health, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸Wake Forest School of Medicine, Winston Salem, NC
Background/Purpose: High titer anti-Ro+ mothers of children with neonatal lupus (NL), often completely asymptomatic, offer a unique opportunity to uncover insights into permissive and protective…
Abstract Number: 0910 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Albert Pérez-Isidro¹, Raul Castellanos-Moreira¹, Juan Camilo Sarmiento-Monroy², Noemi de Moner¹, Maresa Grundhuber³, Odette Vinas¹, Raimon Sanmarti² and Estibaliz Ruiz-Ortiz¹, ¹Hospital Clinic of Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Thermo Fisher Scientific, Freiburg, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].